Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

76 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-05-31

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this protocol is to learn more about impulsive decision making in people who use methamphetamines. The investigators would like to know if a medication called naltrexone changes how people make decisions. The investigators would also like to know whether changes in decision making can be observed by MRI (magnetic resonance imaging).

The research is conducted in Portland, OR.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Facilitating Rapid Naltrexone Initiation

NCT03345173

Opioid Dependence

ACTIVE_NOT_RECRUITING PHASE3

Phase 1 Naltrexone-Bupropion-Methamphetamine Interaction Study

NCT01359930

Methamphetamine Dependence

COMPLETED PHASE1

Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT

NCT01471145

COMPLETED PHASE4

Pharmacogenetics of Naltrexone for Stimulant Abuse

NCT03226223

Substance Use Disorders Methamphetamine Abuse

COMPLETED PHASE2

Study of Naltrexone for Methamphetamine Addiction

NCT00984360

Methamphetamine Dependence

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Methamphetamine Abuse HIV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Extended release naltrexone

One dose of intramuscular injection of 380mg extended-release naltrexone.

Group Type EXPERIMENTAL

Extended release naltrexone

Intervention Type DRUG

Placebo

One dose of intramuscular injection of placebo.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Extended release naltrexone

Intervention Type DRUG

Placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Vivitrol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnostic and Statistical Manual (DSM)-IV Methamphetamine Dependence
* Deemed healthy enough to participate by study physician
* Age 18-55
* Right handed
* English-speaking

Exclusion Criteria

* Current opioid use in the last 30 days; opioid abuse or dependence within past 5 years
* Pregnancy
* MRI contraindications (e.g. metal in head).

The research is conducted in Portland, OR.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No